COMy 2023 | Approaching patients with penta-refractory myeloma: the importance of clinical trials
In this video, Eileen Boyle, MD, PhD, University College London, London, UK, briefly discusses the challenges of treating patients with penta-refractory multiple myeloma, emphasizing the importance of including these patients in clinical trials. This interview took place at the 9th World Congress on Controversies in Multiple Myeloma (COMy) 2023, held in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (edited for clarity)
The penta-refractory are a particularly difficult group of patients to treat as their access to drugs is very limited and these patients are not going to be able to achieve long and sustained responses with the current treatment options we have. So my first approach is always to think of including them in a clinical trial with a drug or a compound that will lead to significant improvement or potential improvement in their quality and length of survival...
The penta-refractory are a particularly difficult group of patients to treat as their access to drugs is very limited and these patients are not going to be able to achieve long and sustained responses with the current treatment options we have. So my first approach is always to think of including them in a clinical trial with a drug or a compound that will lead to significant improvement or potential improvement in their quality and length of survival. And so, this is the first step. The choice of a clinical trial will obviously depend on where you’re working, what is available. But I think as a general group in terms of myeloma experts, it is our duty to provide and maximize the chances for these patients to access novel clinical trials and try and do better for them.
Read more...
